Skip to content
DraconiticResearch
Search Sources API
226,742 studies31 sourcesUpdated 40 min ago
Peer-reviewedCC BY-NC-NDJPGN reports

A real-world comparison of celiac tissue transglutaminase immunoglobulin A antibody levels in pediatric patients using two different diagnostic kits.

7 affiliations
  1. 1Pediatric Gastroenterology Kaplan Medical Center Rehovot Israel.
  2. 2Faculty of Medicine Hebrew University of Jerusalem Jerusalem Israel.
  3. 3Institute of Gastroenterology, Nutrition and Liver Diseases Schneider Children's Medical Center of Israel Petach Tikva Israel.
  4. 4Gray Faculty of Medical and Health Sciences Tel-Aviv University Tel Aviv Israel.
  5. 5Gastroenterology Laboratory, Rabin Medical Center Petach Tikva Israel.
  6. 6Department of Digital Medical technologies Holon Institute of Technology Holon Israel.
  7. 7Data Research Department Academy, Research and Innovation Authority, Kaplan Medical Center Rehovot Israel.

Abstract

Objectives

Pediatric celiac disease (CeD) may be diagnosed without a biopsy when tissue-transglutaminase (TTG) immunoglobulin A (IgA) antibodies are ≥10x the upper limit of normal (ULN) and anti-endomysial antibodies are positive in a second sample. The no-biopsy diagnosis demands a very high accuracy and reliability of the TTG diagnostic kits. Inter-assay differences may affect category classification. We compared TTG-IgA levels performed by two reliable kits: Bioplex 2200 and Liaison-XL in routine care.Methods

Using the Clalit Health Services database, we identified pediatric patients with paired TTG-IgA measurements from both kits within ≤14 days. Values were expressed as multiples of ULN and categorized: 10x ULN. Agreement was assessed for ≤7 and ≤14-day windows using Cohen's ĸ.Results

Category discordance occurred in 17.4% (109/625) of paired tests within 14 days and 11.8% (38/321) within 7 days. Overall agreement was substantial (ĸ = 0.62 for 14 days; ĸ = 0.63 for 7 days). Concordance was high for negative results (96.0%), but significantly lower for the critical >10x ULN threshold at 14 days (88.2%, p = 0.009).Conclusions

Significant discordance between these two reliable TTG-IgA kits at 14 days, exceeding 10% in the >10x ULN category, warrants careful consideration when using the no-biopsy approach for CeD diagnosis, as assay choice may impact clinical classification.

Related

  1. Association Between Tissue Transglutaminase IgA Levels and Villous Atrophy in Pediatric Celiac Disease: A Retrospective Cross-Sectional Study
    Demet TEKER DÜZTAŞ, Gizem AY HALDIZ, Aydın BOZKAYA
    Forbes Tıp DergisiPeer-reviewedCC BY-NCFull textGeneral medicineDOAJ
  2. Characteristics of hospitalized children with immunoglobulin A vasculitis: a 7-year retrospective study of 119,217 pediatric inpatients in China.
    Yue Ma, Xinyu Wang, Ningning Zhang +4
    Frontiers in pediatricsPeer-reviewedCC BYFull textGeneral medicineEurope PMCPMC
  3. Clinical Analysis and Diagnostic Challenges of Immunoglobulin G4-Related Disease Involving the Salivary Gland: A Single Center Retrospective Analysis of 24 Cases
    Tonghui Ding, Hongyuan Chen, Yabing Chen +5
    Medical Science Monitor: International Medical Journal of Experimental and Clinical ResearchPeer-reviewedCC BY-NC-ND 4.0Full textGeneral medicinePMC
  4. PP–005 Same storm, different sparks: pediatric hyperinflammation with distinct underlying triggers
    Ilmay Bilge, Omer Ozden, Bugra Balkan +2
    BMJ Paediatrics OpenPeer-reviewedCC BYObstetrics, gynaecology & paediatricsDOAJ
  5. Multimodal neuroimaging and electrophysiological signatures in amnestic mild cognitive impairment with different amyloid-β deposition status: correlations with cognitive function and diagnostic value
    Yang Liang, Peixue Li, Lin Liu +2
    Frontiers in aging neurosciencePeer-reviewedCC BYFull textGeneral medicineEurope PMC
BibTeX
@article{kori2026realworld,
  title = {{A real-world comparison of celiac tissue transglutaminase immunoglobulin A antibody levels in pediatric patients using two different diagnostic kits.}},
  author = {Michal Kori and Anat Guz-Mark and Tsachi Tsadok Perets and Amit Davidpur and Assaf Hoofien and Raanan Shamir},
  journal = {JPGN reports},
  year = {2026},
  month = nov,
  doi = {10.1002/jpr3.70287},
  url = {https://europepmc.org/article/MED/43011603},
  note = {CC BY-NC-ND},
}
RIS
TY  - JOUR
TI  - A real-world comparison of celiac tissue transglutaminase immunoglobulin A antibody levels in pediatric patients using two different diagnostic kits.
AU  - Michal Kori
AU  - Anat Guz-Mark
AU  - Tsachi Tsadok Perets
AU  - Amit Davidpur
AU  - Assaf Hoofien
AU  - Raanan Shamir
PY  - 2026
DA  - 2026/11/09
JO  - JPGN reports
DO  - 10.1002/jpr3.70287
UR  - https://europepmc.org/article/MED/43011603
AB  - Objectives  Pediatric celiac disease (CeD) may be diagnosed without a biopsy when tissue-transglutaminase (TTG) immunoglobulin A (IgA) antibodies are ≥10x the upper limit of normal (ULN) and anti-endomysial antibodies are positive in a second sample. The no-biopsy diagnosis demands a very high accuracy and reliability of the TTG diagnostic kits. Inter-assay differences may affect category classification. We compared TTG-IgA levels performed by two reliable kits: Bioplex 2200 and Liaison-XL in routine care.Methods  Using the Clalit Health Services database, we identified pediatric patients with paired TTG-IgA measurements from both kits within ≤14 days. Values were expressed as multiples of ULN and categorized: 10x ULN. Agreement was assessed for ≤7 and ≤14-day windows using Cohen's ĸ.Results  Category discordance occurred in 17.4% (109/625) of paired tests within 14 days and 11.8% (38/321) within 7 days. Overall agreement was substantial (ĸ = 0.62 for 14 days; ĸ = 0.63 for 7 days). Concordance was high for negative results (96.0%), but significantly lower for the critical >10x ULN threshold at 14 days (88.2%, p = 0.009).Conclusions  Significant discordance between these two reliable TTG-IgA kits at 14 days, exceeding 10% in the >10x ULN category, warrants careful consideration when using the no-biopsy approach for CeD diagnosis, as assay choice may impact clinical classification.
SN  - 2691-171X
ER  -